Dr. Lei Xia | Theranostics | Best Researcher Award

Posted on by Pencis

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD 🧬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
📞 Phone: 18811177191
✉️ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes 🩻
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes 🧫
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes 🧪
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) 🌟
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) 🌟
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) 🌟
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund 🌟
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund 🌟
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital 🌟
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund 🌟
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

📊🔬Notable Publication:

 

 

 

 

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION:

Citation: 08         Year: 2022

Citation: 01        Year: 2023

 

Prof. Paolo De Simone – Oncology Therapy – Most Liked Article Award

Posted on by Pencis

Prof. Paolo De Simone - Oncology Therapy - Most Liked Article Award

UNIVERSITY OF PISA - Italy

Author Profile

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Paolo De Simone graduated summa cum laude in Medicine and Surgery from the University of Rome La Sapienza. His thesis was titled "Laparoscopic cholecystectomy in the treatment of gallstone lithiasis: prospective analysis of the results of our experience" under the supervision of Prof. Raffaello Cortesini.He earned his Specialist Diploma in General Surgery summa cum laude from the University of Rome “La Sapienza”. His thesis focused on "The role of laparoscopic surgery in the treatment of benign and malignant gastric pathologies" under the guidance of Prof. Raffaello Cortesini.Paolo De Simone achieved his PhD summa cum laude in Surgical Pathophysiology.

PROFESSIONAL ENDEAVORS

Registered in the Order of Doctors-Surgeons and Dentists of the Province of Rome with registration number 46702. He also qualified to practice the medical-surgical profession at the University of Rome “La Sapienza”. He served as a Foreign Resident-Assistant at the General Surgery Service of CHU André Vésale, Université Libre de Bruxelles, Montigny-Le-Tilleul, Belgium, and at the Thoracic and Vascular Surgery Service of the Hospital Avicenne, Bobigny, France. Paolo De Simone held several medical director positions:General Surgery Unit, Civil Hospital of Vittorio Veneto (TV),Organ Transplant Unit, San Salvatore Civil Hospital, L'Aquila,Service de Chirurgie Digestive, Hopital Erasme, Université Libre de Bruxelles, Brussels,University Liver Transplantology Unit, Pisa University Hospital.Currently, he is an Associate Professor of Surgery at the University of Pisa. He was elected Director of the School of Specialization in Surgery of the Digestive System and serves as Director of the Liver Surgery and Liver Transplant Unit, AOUP.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPY

Appointed as the Coordinator of the regional liver transplant program by DGRT of 17 December 2018, n. 1450. He also managed clinical, scientific, and educational coordination of terminal liver failure and liver transplantation (DG AOUP Resolution 852 of 09/20/2023).His research has covered areas like laparoscopic cholecystectomy, treatment of benign and malignant gastric pathologies, and liver transplantology.

IMPACT AND INFLUENCE

As Coordinator of the Liver Transplant Program of the Tuscany Region, he has significantly contributed to the advancement of liver transplantation in the region.

LEGACY AND FUTURE CONTRIBUTIONS

Paolo De Simone's legacy lies in his extensive contributions to the fields of general surgery, liver surgery, and liver transplantology. His future contributions are anticipated in enhancing liver transplant programs, furthering research in surgical pathophysiology, and mentoring the next generation of surgeons through his academic roles.

NOTABLE PUBLICATIONS

Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation.

First-in-human liver transplantation from a centenarian deceased donor after brain death.

Aging with a Liver Graft: Analysis of Very Long-Term Survivors after Liver Transplantation.

An Unexpected Case of Opisthorchis felineus Infection Revealed during Liver Transplantation.

An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients.